Propanc Biopharma, Inc. Common Stock (PPCB) Stock Price
PPCBStock
$1.13−98.63%52W
Market Cap$2.57M
P/E—
PEG Ratio—
Div yield—
Beta3.14
PPCB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-89.25%
Price vs S&P 500 (4W)-7.60%
VGM Score5.42
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PPCBPropanc Biopharma, Inc. Common Stock | — | F | F | $1.13 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma is a development-stage biopharmaceutical company focused on oncology treatments for pancreatic, ovarian, and colorectal cancers. The company's lead candidate, PRP, is a composite formulation designed to prevent tumor recurrence and metastasis through a novel proenzyme-based approach. The product combines multiple anti-cancer mechanisms intended to improve treatment outcomes in difficult-to-treat solid tumors.